May 08, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 20, 2026

Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians

Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).

Dana-Farber

April 08, 2026

Metastatic Papillary Renal Cancer: Final Results With Savolitinib and Durvalumab

As reported in the Journal of Clinical Oncology by Jackson-Spence et al, final results of the phase II CALYPSO study indicated better overall survival and other outcomes with savolitinib and durvaluma...

The ASCO Post

April 01, 2026

Dana-Farber Research News 04.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.

Dana-Farber

March 31, 2026

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post